CAR-T cell therapy targeting CD70 for advanced solid tumors
Treatments studied
Part of Cancer, Ear, nose & throat, Hormones & metabolism, Kidney & urinary, Mouth & dental, Women’s health & pregnancy clinical trials.
This trial tests a new type of immune cell therapy (CAR-T) that targets a protein called CD70 found on some solid tumors. It is for people whose cancer has not responded to other treatments and whose tumor tests positive for CD70. The goal is to see if this treatment can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor (like lung, breast, or colon cancer) that has not responded to at least two prior treatments, or there is no standard first treatment option for your type of cancer.
- Your tumor must test positive for a protein called CD70 (a marker that the CAR-T cells target).
- You must be 18 years or older and have a performance status of 0 or 1 (meaning you are generally active and able to care for yourself).
- You must have at least one measurable tumor on a scan, and your expected survival is more than 12 weeks.
- Your blood counts, liver, kidney, and heart function need to be within safe ranges as determined by standard lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new treatment using your own immune cells (CAR-T cells) designed to attack cancer cells that have a protein called CD70. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Hear when a new Metastatic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.